# SCHEDULE

**Course:** CLRE-236 – Translational Research Fundamentals - From Bench to Bedside and Back  
**Course Director:** Régent Laporte, D.V.M., M.Sc., Ph.D.  
**Course Assistant Director:** Kanthi Athreya Kollengode, M.D., M.A.S.  
**Course Teaching Assistant:** Oluwakemi “Kemi” Okwuegbuna, M.D., F.M.C.Path., M.Sc.  
**Quarter:** Summer 2018  
**Class Time:** Fridays from 2:00 to 3:50 PM, from July 6th to September 14th, 2018  
**Class Location:** UCSD Extension, Suite 150, Room 111 - University City Center, 6256 Greenwich Dr., San Diego, CA 92122

<table>
<thead>
<tr>
<th>Lesson (Date)</th>
<th>Topic</th>
<th>Learning Objectives</th>
<th>Textbook Sections</th>
<th>Evaluation (Points)</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 1 (07/06)     | Introduction & Definitions  
**The Changing Role of Big Pharma Biomarkers** | • Define Translational Medicine, explain why it is needed, what are its main remits, what is its current challenge, and what is the NIH Roadmap  
• Describe how Translational Medicine is changing Big Pharma Drug Discovery & Development  
• Define biomarkers and describe their impact and remits in drug development  
• Describe how biomarkers could be used for decision making in drug development  
• Describe how biomarkers could be developed  
• Describe the predictivity classification of biomarkers and scores  
• Describe the use and value of biomarkers for health authorities and consortia  
• Describe the principles and types of tissue biobanks and the current challenges that they are facing  
• Describe the main biomarker localization technologies and immunoassays and their values for molecular medicine | 1, 9, 10  
3.1  
3.2  
3.3  
3.4  
2.1.8  
2.1.5  
2.1.7 | 2.5 | 5 | Régent Laporte  
Kanthi A. Kollengode |
| 2 (07/13)     | Diagnostics | • Define a diagnostic test  
• Evaluate when it is appropriate to use a diagnostic test  
• Learn the main quantitative aspects of a diagnostic test  
• Describe the paradigm shift that led to the discovery and development of companion diagnostics and list 3 merits and demerits of the same with examples  
• What are complementary diagnostics and how do they differ from companion diagnostics  
• Describe 3 key elements that distinguish point-of-care testing from centralized laboratory testing and list 3 limitations of the same | Reviews from the literature | 2.5 | 5 | Roberta V. Alexander  
Kanthi A. Kollengode |
<p>| 3 (07/20)     | Intellectual Property &amp; Innovation | • Define what is intellectual property (IP) in Translational Medicine | 7 | 2.5 | 5 | Michael K. Dunn |
| 4 (07/27)     | The Omics | • Define the “Oomics” and their roles in Translational Medicine | 2.1.1, 2.1.2 | 2.5 | 7.5 | Timothy R. Geiger |
| 5 (08/03)     | Translational Imaging | • List the main translational imaging modalities and describe how they can be used in Drug Discovery &amp; Development | 3.7.3 | 2.5 | 5 | Patrick McConville |</p>
<table>
<thead>
<tr>
<th>Lesson (Date)</th>
<th>Topic</th>
<th>Learning Objectives</th>
<th>Textbook Sections</th>
<th>Evaluation (Points)</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 (08/10)</td>
<td>Pharmacogenomics-Driven Treatment</td>
<td>• Explain the role of Translational Pharmacogenetics in driving clinical decision making related to drug therapies</td>
<td>2.1.4 2.5 5</td>
<td>Grace M. Kuo</td>
<td></td>
</tr>
</tbody>
</table>
| 7 (08/17)   | Drug Discovery | • Understand the place, role and purpose of Drug Discovery (i.e., Research) within Pharmaceutical Research & Development (R&D)  
• Integrate the business and economic considerations impacting drug discovery programs  
• Recognize and appreciate the diversity of therapeutic modalities and their respective strengths and limitations  
• Map the drug discovery processes, from conception to execution | Reviews from the literature | Pierre J.-M. Rivière |
| 8 (08/24)   | Non-Clinical Development | • Describe what is regulatory non-clinical assessment in drug development | 5 2.5 5 | Marina S. Nelson |
| 9 (08/31)   | Clinical Development | • Describe the methodological principles of Phase I clinical trials  
• Define what are Phase 0 clinical trials (a.k.a. exploratory clinical trials/studies) and how they can be used in drug development  
• Describe what is adaptive trial design  
• Describe what are basket or umbrella trial designs  
• Describe how regulatory and exploratory clinical trials could be combined and accelerate the generation of a clinical proof of concept | 4.1 4.2, 4.3 4.4 4.5, 4.6 | Mark S. Hixon |
| 10 (09/07)  | Translational Stem Cell Research | • Explain the challenges associated with Translational Stem Cell Research  
• Explain how Stem-Cell-Derived Therapies Discovery & Development differs from Drug Discovery & Development  
• List the Stem-Cell-Derived Therapies and illustrate their applications | Reviews from the literature | Catriona Jamieson |
| Final Exam (09/14) | Final Exam | 20 Points | | |

**TOTAL** 25 55

**Faculty**

Robert V. Alexander, Pharm.D., Ph.D.  
Associate Director of Clinical Research & Medical Affairs  
Exagen Diagnostics

Michael K. Dunn, Ph.D., M.B.A.  
Senior Director, Scientific Information & Intelligence  
Ferring Pharmaceuticals

Timothy R. Geiger, Ph.D.  
Field Applications Manager - North America West  
ProteinSimple

Mark S. Hixon, Ph.D.  
Principal  
Mark S. Hixon Consulting LLC

Catriona Jamieson, M.D., Ph.D.  
Professor of Medicine, Koman Family Presidential Endowed Chair in Cancer Research  
Chief, Division of Regenerative Medicine  
Director, CIRM Alpha Stem Cell Clinic at UC San Diego  
Deputy Director, Sanford Stem Cell Clinical Center  
Co-Leader, Hematologic Malignancies Program  
Director, Moores Cancer Center Stem Cell Research Program  
University of California, San Diego

Kanthi A. Kollengode, M.D., M.A.S.  
Bio Nova Institute

Grace M. Kuo, Pharm.D., Ph.D., M.P.H., F.C.C.P.  
Professor of Clinical Pharmacy  
Associate Dean for Strategic Planning and Program Development
Skaggs School of Pharmacy and Pharmaceutical Sciences
Adjunct Professor of Family and Preventive Medicine
Director of SDPharmNet™ & PharmGenEd™
University of California, San Diego

Régent Laporte, D.V.M., M.Sc., Ph.D.
Principal Consultant, Laporte & Associates LLC
Senior Director, Translational Pharmacology, Peptide Logic, LLC
Research Fellow, Bio Nova Institute

Patrick McConville, Ph.D.
Vice-President, Non-Clinical Research Services, inviCRO, LLC
Adjunct Professor, Department of Radiology, School of Medicine
University of California, San Diego

Marina S. Nelson, Ph.D.
Drug Development Leader, Early Phase Development Solutions
Covance Laboratories

Pierre J.-M. Rivière, Ph.D.
CEO, Peptide Logic, LLC
Research Fellow, Bio Nova Institute